Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy-Reference-Cited by-同舟云学术

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy

Published:2016-08-26 Issue:12 Volume:29 Page:1565-1574
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Lahdensuo Kanerva,Erickson Andrew,Saarinen Irena,Seikkula Heikki,Lundin Johan,Lundin Mikael,Nordling Stig,Bützow Anna,Vasarainen Hanna,Boström Peter J,Taimen Pekka,Rannikko Antti,Mirtti Tuomas

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2016154.pdf

Reference37 articles.

1. Center MM, Jemal A, Lortet-Tieulent J et al.International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–1092.

2. Epstein JI . An update of the Gleason grading system. J Urol 2010;183:433–440.

3. Epstein JI, Egevad L, Amin MB et al.The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016;40:244–252.

4. Bostrom PJ, Bjartell AS, Catto JW et al.Genomic predictors of outcome in prostate cancer. Eur Urol 2015;68:1033–1044.

5. Zhao L, Yu N, Guo T et al.Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1047–1054.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs;International Journal of Molecular Sciences;2023-09-03

2. PTEN loss in intraductal carcinoma of the prostate has low incidence in Japanese patients;Pathology International;2023-08-23

3. Serrate RNA Effector Molecule (SRRT) Is Associated with Prostate Cancer Progression and Is a Predictor of Poor Prognosis in Lethal Prostate Cancer;Cancers;2023-05-22

4. PP2A methylesterase PME ‐1 suppresses anoikis and is associated with therapy relapse of PTEN ‐deficient prostate cancers;Molecular Oncology;2023-04-18

5. Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy;Archivio Italiano di Urologia e Andrologia;2022-12-27